Abstract
Although the majority of thyroid cancer patients presenting to our surgical endocrinology clinics present with resectable and often curable disease, patients may rarely present with a history and physical findings suggestive of an anaplastic thyroid cancer. The endocrine surgeon should recognize, diagnose, and treat this patient urgently and promptly. The clinical course and findings from two patients who presented to our endocrine surgery clinic recently are summarized below from the patients’ clinical notes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Are C, Shaha AR (2006) Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453–464
Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 83:2638–2648
Demeter JG, De Jong SA, Lawrence AM, Paloyan E (1991) Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 110:956–961; discussion 961–963
Nikiforova MN, Kimura ET, Gandhi M et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404
Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X (2005) Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103:2261–2268
Tallini G, Santoro M, Helie M et al (1998) RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4:287–294
McIver B, Hay ID, Giuffrida DF et al (2001) Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028–1034
Tennvall J, Lundell G, Wahlberg P et al (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86:1848–1853
Haigh PI, Ituarte PH, Wu HS et al (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335–2342
Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA (1990) Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 66:321–330
Nilsson O, Lindeberg J, Zedenius J et al (1998) Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 22:725–730
Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J (2006) Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 107:1786–1792
Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587–594
Ain KB, Tofiq S, Taylor KD (1996) Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81:3650–3653
Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ (2005) Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 131:585–590
Yeung SC, Xu G, Pan J, Christgen M, Bamiagis A (2000) Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 60:650–656
Xu G, Pan J, Martin C, Yeung SC (2001) Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86:1769–1777
Dackiw A, Pan J, Xu G, Yeung SC (2005) Modulation of parathyroid hormone-related protein levels (PTHrP) in anaplastic thyroid cancer. Surgery 138:456–463
Nagayama Y, Yokoi H, Takeda K et al (2000) Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85:4081–4086
Narimatsu M, Nagayama Y, Akino K et al (1998) Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab 83:3668–3672
Copland JA, Marlow LA, Kurakata S et al (2006) Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25:2304–2317
Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17–44
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
This chapter is dedicated to the memory of my patients I have cared for, who have suffered anaplastic thyroid cancer and also their families and to the hope that we will soon have more effective treatments strategies for their therapy.
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Dackiw, A.P.B. (2010). Anaplastic Thyroid Cancer. In: Sturgeon, C. (eds) Endocrine Neoplasia. Cancer Treatment and Research, vol 153. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0857-5_5
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0857-5_5
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-0856-8
Online ISBN: 978-1-4419-0857-5
eBook Packages: MedicineMedicine (R0)